Shire announces positive outcome from European regulatory approval of Elvanse

Shire announces a positive outcome from the European Decentralised Procedure for Elvanse. Elvanse is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate.

View Comments (0)